Dagens oppgang vil jeg tilskrive denne nyheten fra konkurrent Therorna https://www.businesswire.com/news/home/20260511897230/en/Therorna-to-Showcase-Clinical-Ready-Circular-RNA-in-vivo-CAR-T-and-CircRNA-Pipeline-at-the-2026-American-Society-of-Gene-Cell-Therapy-ASGCT-Annual-Meeting?utm_campaign=shareaholic&utm_medium=copy_link&utm_source=bookmark
Spesielt dette " * In humanized mouse models: robust in vivo CAR expression in CD8⁺ T cells across both the blood and tissues after a single dose; complete B-cell depletion within 24 hours; and complete tumor regression in the Nalm6 lymphoma model at 0.02 mg/kg (0.4 μg/mouse)".
Selvom det er en konkurrent så vil jeg si at deres data både validerer og derisker kommende car-t data til Circio. Jeg tror Circio vil vise høyere og lengre uttrykk i milten enn Therorna.

sitter fortsatt (per i går) “musestille”
siden 4 mai.






).